Shots:

• The approval is based on the P-III VICTORIA trial involves assessing Verquvo (2.5mg- 5mg & 10mg) in patients with CHF- published in NEJM in Mar’20. The therapy is being jointly developed with MSD
• The therapy has been studied specifically for patients who have experienced recent worsening HF events to reduce the risk of further worsening events. Additionally- therapy has been submitted for marketing authorization in China along with multiple other countries globally
• Vericiguat is the 1st sGC stimulator- received the US FDA’s approval in Jan’21 and CHMP has recommended for marketing authorization in EU in May’21

  | Ref: Bayer | Image: The Business Journals